Biology Newsfeed

[Special Issue Review] Drugging RAS: Know the enemy

ScienceNOW - Fetched: March 16th, 2017, 4:00pm UTC

The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable. However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered. Here we summarize where these efforts stand. Authors: Bjoern Papke, Channing J. Der

Read more

Return to the Newsfeed